China Traditional Chinese Medicine Holdings Co. Limited has announced that the National Medical Products Administration (NMPA) of China has accepted the new drug application for Yushuda Tablets, a Class 1.1 innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. The acceptance marks the start of a series of regulatory review procedures, including technical evaluation and on-site inspection. Yushuda Tablets have shown significant efficacy in treating symptoms associated with qi stagnation and mild-to-moderate depression. While this is a promising development, the timeline for final approval remains uncertain, and shareholders are advised to exercise caution.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。